Cargando…

Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12

PURPOSE: This study was conducted to determine the effectiveness of immune checkpoint inhibitors (ICIs) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum-containing chemotherapy. We also identified clinical biomarkers which may be predictive of patient progn...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Yun-Gyoo, Chang, Hyun, Keam, Bhumsuk, Chun, Sang Hoon, Park, Jihyun, Park, Keon Uk, Shin, Seong Hoon, An, Ho Jung, Lee, Kyoung Eun, Lee, Keun-Wook, Kim, Hye Ryun, Kim, Sung-Bae, Ahn, Myung-Ju, Hwang, In Gyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291197/ https://www.ncbi.nlm.nih.gov/pubmed/33285051 http://dx.doi.org/10.4143/crt.2020.824

Ejemplares similares

Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01)
por: Kang, Eun Joo, et al.
Publicado: (2022)

Comparison of Treatment Patterns and Clinical Outcomes by Gender in Locally Advanced Head and Neck Squamous Cell Carcinoma (KCSG HN13-01)
por: Lee, Yun-Gyoo, et al.
Publicado: (2023)

Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13–01)
por: Lee, Yun-Gyoo, et al.
Publicado: (2020)

Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01)
por: Lee, Yun-Gyoo, et al.
Publicado: (2022)

Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG‐LU16‐07
por: Kim, Miso, et al.
Publicado: (2020)

Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05)
por: Choi, Yoon Ji, et al.
Publicado: (2018)

A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
por: Lee, Dae-Won, et al.
Publicado: (2023)

Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22
por: Jung, Hyun Ae, et al.
Publicado: (2022)

Long‐term outcomes in patients with advanced and/or metastatic non–small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real‐world data (KCSG LU20‐11)
por: Kim, Hongsik, et al.
Publicado: (2021)

Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)
por: Sim, Sung Hoon, et al.
Publicado: (2022)

Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09)
por: Lee, Jieun, et al.
Publicado: (2023)

Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18
por: Kim, M., et al.
Publicado: (2023)

Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study
por: Kim, Jin Won, et al.
Publicado: (2018)

Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study
por: Hwang, In Gyu, et al.
Publicado: (2021)

Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
por: Kim, Miso, et al.
Publicado: (2017)

A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
por: Yoo, Kwai Han, et al.
Publicado: (2019)

Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
por: Sim, Sung Hoon, et al.
Publicado: (2019)

Treatment outcomes of advanced/metastatic extramammary Paget's disease in Korean patients: KCSG‐RC20‐06
por: Sohn, Byeong Seok, et al.
Publicado: (2023)

A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First‐line Therapy (KCSG ST10‐01)
por: Lee, Keun‐Wook, et al.
Publicado: (2018)

Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
por: Park, In Hae, et al.
Publicado: (2019)

AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20)
por: Suh, Koung Jin, et al.
Publicado: (2023)

TRIUMPH Trial: One Small Step Could Become One Giant Leap for Precision Oncology in Head and Neck Cancer
por: Keam, Bhumsuk, et al.
Publicado: (2019)

Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07)
por: Sun, Jong-Mu, et al.
Publicado: (2018)

Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
por: Han, Hye Sook, et al.
Publicado: (2021)

Immune-Checkpoint-Inhibitor-Induced Severe Autoimmune Encephalitis Treated by Steroid and Intravenous Immunoglobulin
por: Kim, Ahwon, et al.
Publicado: (2019)

Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
por: Cho, Kyoung Min, et al.
Publicado: (2015)

Comparative effectiveness of palliative chemotherapy versus neoadjuvant chemotherapy followed by radical cystectomy versus cystectomy followed by adjuvant chemotherapy versus cystectomy for regional node‐positive bladder cancer: A retrospective analysis: KCSG GU 17‐03
por: Bae, Woo Kyun, et al.
Publicado: (2019)

Prognostic Value of CD200R1 mRNA Expression in Head and Neck Squamous Cell Carcinoma
por: Chang, Hyun, et al.
Publicado: (2020)

Pneumatosis Intestinalis with Pneumoperitoneum Mimicking Intestinal Perforation in a Patient with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation
por: Keam, Bhumsuk, et al.
Publicado: (2007)

Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future Directions
por: Lee, Dae-Won, et al.
Publicado: (2016)

A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)
por: Kim, Hye Ryun, et al.
Publicado: (2016)

Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients
por: Beom, Seung-Hoon, et al.
Publicado: (2016)

A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09
por: Lee, Ki Hyeong, et al.
Publicado: (2015)

Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)
por: Kim, Hye Ryun, et al.
Publicado: (2017)

Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Kim, Jwa Hoon, et al.
Publicado: (2022)

A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10)
por: Lee, Keun-Wook, et al.
Publicado: (2023)

Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations
por: Park, Sehhoon, et al.
Publicado: (2016)

KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer
por: Park, Sehhoon, et al.
Publicado: (2017)

Cancer Treatment near the End-of-Life Becomes More Aggressive: Changes in Trend during 10 Years at a Single Institute
por: Choi, Younak, et al.
Publicado: (2015)

The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase‐positive non‐small cell lung cancer
por: Heo, Ja Yoon, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gk11ag2ggiq1765huf4v4p0rg0